Science publications

09 June 2024

Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial

GSK authors: M. Marco Balas; Ma. Grimshaw; S. Stevens; D.W. Lai

02 June 2024

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

GSK authors: Kristin Morris, Pharm.D; Farrah Pompilus, PhD; Amy Phillips-Jones, MSc; Giulia Fulci, PhD; Neal Sule, MB; Brandon E. Kremer, MD; PhD; Joanna Opalinska, MD, PhD

01 June 2024

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

GSK authors: Kihyun Kim, MD; Nick Pirooz, MHA; Astrid McKeown, PhD; Simon McNamara, PhD; Xiangdong Zhou, PhD; Maureen Nichols, BS; Eric Lewis, MD; Rachel Rogers, MS.; Hena Baig, BS; Lydia Eccersley, MB, BS, PhD; Sumita Roy-Ghanta, MD; Joanna Opalinska, MD

08 February 2024

Gepotidacin, a new first-in-class antibiotic for treating uncomplicated urinary tract infection

08 February 2024

Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials

GSK authors: Caroline R Perry, PHD; Nicole E Scangarella-Oman, MSc; Helen Millns, PHD; Marcy Powell, MD

08 January 2024

Multiple antigen presenting system (MAPS): state of the art and potential applications

GSK authors: Shite Sebastian; Fan Zhang; David O. Willer

27 July 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

GSK authors: Barbara J Klencke, MD; Jing Yu, PhD; Rafe Donahue, PhD; Jun Kawashima, MD

08 June 2023

Dostarlimab for primary advanced or recurrent endometrial cancer

GSK authors: Min Tian, PhD; Zangdong He, PhD; Shadi Stevens, MD; Eleftherios Zografos, MD; Matthew A. Powell, MD​

16 February 2023

Respiratory syncytial virus prefusion F protein vaccine in older adults

GSK authors: Nancy Dezutter, PhD; Nathalie de Schrevel, PhD; Laurence Fissette, MS; Marie-Pierre David, MS; Marie Van der Wielen, MD; Lusine Kostanyan, MD; Veronica Hulstrøm, MD, PhD

28 January 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

GSK authors: Barbara J Klencke, MD; Sunhee Ro, PhD; Rafe Donahue, PhD; Jun Kawashima, MD

24 November 2022

Efficacy and safety of bepirovirsen in chronic hepatitis B infection

GSK authors: Jennifer Cremer, PharmD; Robert Elston, PhD; Tamara Lukić, MD; Geoff Quinn, MSc; Lauren Maynard, MSc; Stuart Kendrick, PhD; Helene Plein, PhD; Melanie Paff, PhD; and Dickens Theodore, MD, MPH

29 July 2022

Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years

GSK authors: Frank Malinoski; Shite Sebastian; George Siber; Richard Malley